Comparison of Efficacy of Phenytoin With Levetireacetam for the Management of Children With Status Epilepticus
NCT ID: NCT04829838
Last Updated: 2021-04-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
244 participants
INTERVENTIONAL
2019-07-25
2021-07-26
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy Comparison Between Levetiracetam and Valproic Acid in Pediatric Patients With Status Epilepticus
NCT07052136
Efficacy of Phenytoin vs Levetiracetam in Status Epilepticus at Institute of Child Health,Faisalabad
NCT06067412
Levetiracetam Versus Phenytoin in Management of Pediatric Status Epilepticus
NCT04176887
Comparison of Intravenous Brivaracetam Versus Levetiracetam in the Management of Status Epilepticus
NCT07163572
The Efficacy and Safety of Levetiracetam Versus Fosphenytoin in Convulsive Status Epilepticus
NCT06403150
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
FACTORIAL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Intravenous levetireacetam
Drug:Intravenous levetireacetam will be given at a loading dose of 20-30mg/kg then it will be added in maintainance dose of (5-30mg/kg/day)
intravenous levetireacetam
phenytoin is considered as control drug in the study
intravenous phenytoin
Intravenous phenytoin will be given in loading dose of 20mg/kg then it will be added in maintainance dose i-e 5-8mg/kg/day
intravenous levetireacetam
phenytoin is considered as control drug in the study
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
intravenous levetireacetam
phenytoin is considered as control drug in the study
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
2 Months
12 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
King Edward Medical University
OTHER
ayesha tariq
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
ayesha tariq
Post graduate resident in Pediatrics medicine(MD Paeds)
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Haroon Hamid, MBBS,FCPS
Role: PRINCIPAL_INVESTIGATOR
King Edward Medical University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ayesha Tariq
Lahore, Punjab Province, Pakistan
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Smith DM, McGinnis EL, Walleigh DJ, Abend NS. Management of Status Epilepticus in Children. J Clin Med. 2016 Apr 13;5(4):47. doi: 10.3390/jcm5040047.
Abend NS, Loddenkemper T. Pediatric status epilepticus management. Curr Opin Pediatr. 2014 Dec;26(6):668-74. doi: 10.1097/MOP.0000000000000154.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
700/RC/KEMU
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.